#United States #FDA Approval #Glenmark Pharmaceuticals #Fluticasone Propionate #Elmwood Park, NJ

Glenmark Specialty SA Achieves FDA Green Light for Fluticasone Propionate Inhalation Aerosol

In a significant advancement for respiratory health treatments, Glenmark Specialty SA has obtained final approval from the United States Food and Drug Administration (U.S. FDA) for its Fluticasone Propionate Inhalation Aerosol, delivering a dosage of 44 mcg per actuation. This approval aligns Glenmark's product with the established standards, confirming it as bioequivalent and therapeutically equivalent to the well-known FloVent® HFA Inhalation Aerosol, which is marketed by GlaxoSmithKline.

The FDA's decision designates Glenmark's Fluticasone as a Competitive Generic Therapy (CGT), granting it a unique position as the "first approved applicant" under specific conditions set forth in the FDA regulations. This designation not only allows Glenmark to establish its product in the market swiftly but also secures a competitive window of 180 days of exclusivity. With an expected launch in March 2026, Glenmark's initiative is positioned to underscore its commitment to enhancing access to quality inhalation therapies across the U.S.

With a market reach poised to deliver significant sales, the FloVent® HFA Inhalation Aerosol recorded approximately $520.1 million in annual sales for the year ending January 2026. This financial backdrop highlights not just the potential commercial opportunity for Glenmark but also the clinical necessity for effective inhalation treatments in the respiratory sector.

Marc Kikuchi, President and Business Head for North America at Glenmark, emphasized the importance of this development, stating, "Receiving approval for Fluticasone Propionate Inhalation Aerosol USP represents a pivotal milestone in bolstering our respiratory portfolio in the U.S. The CGT designation and first approved applicant status validate our team's technical know-how and dedication to introducing complex inhalation therapies to the market. We are committed to providing affordable and high-quality respiratory options to enhance patient care and support healthcare providers."

Glenmark's Fluticasone Propionate Inhalation Aerosol is specifically approved for the indications mentioned in the product's labeled information. It is essential to remember that while many brands and trademarks exist within this domain, Glenmark's product adheres strictly to the approved indicators.

As a global entity, Glenmark Pharmaceuticals Limited, trading under stock codes BSE 532296 and NSE GLENMARK, has a strong presence with 11 state-of-the-art manufacturing facilities across four continents, operating with the mission to bring innovative and accessible healthcare solutions to patients worldwide. The firm’s focus on developing life-saving treatments in the areas of respiratory conditions, dermatology, and oncology has established it within the upper echelon of the biopharmaceutical field, securing its market position as one of the top 100 biopharma companies as recognized by Scrip in 2024.

In a world where respiratory ailments remain prevalent, and access to effective inhalation therapies continues to be a pressing issue, Glenmark's latest approval is set to make a meaningful difference. It not only reflects the company's ongoing commitment to innovation but also reinforces its role in the transformation of healthcare access, ultimately aiding countless patients in their need for effective respiratory solutions.